他汀类药物基因组学：寻找预测临床结局的生物标志物。
Statin pharmacogenomics: pursuing biomarkers for predicting clinical outcomes.
作者信息
Kitzmiller Joseph P, Binkley Philip F, Pandey Saurabh R, Suhy Adam M, Baldassarre Damiano, Hartmann Katherine
机构信息
College of Medicine, The Ohio State University, Columbus, Ohio 43210, USA.
出版信息
Discov Med. 2013 Aug;16(86):45-51.
Abstract
Indicated for treating hyperlipidemias and for the prevention of cardiovascular disease (CVD), statins rank among the most commonly prescribed drug classes. While statins are considered to be highly effective in preventing atherosclerotic events, a substantial portion of treated patients still progress to overt CVD. Genetic factors are thought to contribute substantially to treatment outcome. Several candidate genes have been associated with statin dose requirements and treatment outcomes, but a clinically relevant pharmacogenomics test to guide statin therapy has not yet emerged. Here we define basic pharmacogenomics terminology, present strong candidate genes (CETP, HMGCR, SLCO1B1, ABCB1, and CYP3A4/5), and discuss the challenges in developing much-needed statin pharmacogenomics biomarkers for predicting treatment outcomes.
摘要
他汀类药物被用于治疗高脂血症和预防心血管疾病（CVD），是最常被处方的药物类别之一。虽然他汀类药物在预防动脉粥样硬化事件方面被认为非常有效，但仍有相当一部分接受治疗的患者会发展为明显的心血管疾病。遗传因素被认为在很大程度上影响治疗效果。几个候选基因已被发现与他汀类药物的剂量需求和治疗效果相关，但尚未出现一种临床上相关的药物基因组学检测方法来指导他汀类药物治疗。在这里，我们定义了基本的药物基因组学术语，介绍了强有力的候选基因（CETP、HMGCR、SLCO1B1、ABCB1和CYP3A4/5），并讨论了开发急需的用于预测治疗效果的他汀类药物药物基因组学生物标志物所面临的挑战。
相似文献
1
Statin pharmacogenomics: pursuing biomarkers for predicting clinical outcomes.
Discov Med. 2013 Aug;16(86):45-51.
2
Pharmacogenomics of statin therapy: any new insights in efficacy or safety?
Curr Opin Lipidol. 2014 Dec;25(6):438-45. doi: 10.1097/MOL.0000000000000125.
3
Genomic Variations Affecting Biological Effects of Statins.
Curr Drug Metab. 2016;17(6):566-72. doi: 10.2174/1389200217666160219114116.
4
Statins and myotoxicity: a therapeutic limitation.
Expert Opin Drug Saf. 2006 Sep;5(5):651-66. doi: 10.1517/14740338.5.5.651.
5
Pharmacogenomics of statin response.
Curr Opin Mol Ther. 2008 Dec;10(6):555-61.
6
Connecting the role of C-reactive protein and statins in cardiovascular disease.
Clin Cardiol. 2003 Apr;26(4 Suppl 3):III39-44. doi: 10.1002/clc.4960261508.
7
Clinical implications of pharmacogenetic variation on the effects of statins.
Drug Saf. 2011 Jan 1;34(1):1-19. doi: 10.2165/11584380-000000000-00000.
8
Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Clin Ther. 2009 Dec;31(12):2919-30; discussion 2916-8. doi: 10.1016/j.clinthera.2009.12.013.
9
Statins: have we found the Holy Grail?
Swiss Med Wkly. 2012 Feb 3;142:w13515. doi: 10.4414/smw.2012.13515. eCollection 2012.
10
[Can genes predict the response to treatment with statins?].
Med Clin (Barc). 2003 Oct 25;121(14):535-6. doi: 10.1016/s0025-7753(03)74010-x.
引用本文的文献
1
Investigating the role of genetic variations of (rs1045642) and (rs3808607) genes on serum lipid level among Malaysian male patients treated with atorvastatin.
Saudi Med J. 2025 Aug;46(8):898-906. doi: 10.15537/smj.2025.46.8.20250310.
2
Frameshift variation in the HMG-CoA reductase gene and unresponsiveness to cholesterol-lowering drugs in type 2 diabetes mellitus patients.
Sci Rep. 2025 Jan 2;15(1):288. doi: 10.1038/s41598-024-75461-7.
3
Statins-Beyond Their Use in Hypercholesterolemia: Focus on the Pediatric Population.
Children (Basel). 2024 Jan 17;11(1):117. doi: 10.3390/children11010117.
4
Association between single nucleotide polymorphism SLCO1B1 gene and simvastatin pleiotropic effects measured through flow-mediated dilation endothelial function parameters.
Ther Adv Cardiovasc Dis. 2022 Jan-Dec;16:17539447221132367. doi: 10.1177/17539447221132367.
5
Association of cytochromes P450 3A4*22 and 3A5*3 genotypes and polymorphism with response to simvastatin in hypercholesterolemia patients.
PLoS One. 2022 Jul 15;17(7):e0260824. doi: 10.1371/journal.pone.0260824. eCollection 2022.
6
Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease.
Heart. 2019 Jul;105(13):975-981. doi: 10.1136/heartjnl-2018-314253. Epub 2019 Apr 15.
7
KIF6 gene as a pharmacogenetic marker for lipid-lowering effect in statin treatment.
PLoS One. 2018 Oct 10;13(10):e0205430. doi: 10.1371/journal.pone.0205430. eCollection 2018.
8
Value of a Hypothetical Pharmacogenomic Test for the Diagnosis of Statin-Induced Myopathy in Patients at High Cardiovascular Risk.
Mol Diagn Ther. 2018 Dec;22(6):641-652. doi: 10.1007/s40291-018-0356-6.
9
Economic Evaluation of a Pharmacogenomics Test for Statin-Induced Myopathy in Cardiovascular High-Risk Patients Initiating a Statin.
Mol Diagn Ther. 2017 Feb;21(1):95-105. doi: 10.1007/s40291-016-0238-8.
10
Frequency distribution of polymorphisms of CYP2C19, CYP2C9, VKORC1 and SLCO1B1 genes in the Yakut population.
Res Pharm Sci. 2016 May-Jun;11(3):259-64.
本文引用的文献
1
Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy.
Arthritis Rheum. 2012 Dec;64(12):4087-93. doi: 10.1002/art.34673.
2
Cholesteryl Ester Transfer Protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk.
PLoS One. 2012;7(3):e31930. doi: 10.1371/journal.pone.0031930. Epub 2012 Mar 5.
3
Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin.
Pharmacotherapy. 2011 Oct;31(10):942-50. doi: 10.1592/phco.31.10.942.
4
Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study.
Pharmacogenet Genomics. 2011 Dec;21(12):861-6. doi: 10.1097/FPC.0b013e32834c6edb.
5
The use of phenome-wide association studies (PheWAS) for exploration of novel genotype-phenotype relationships and pleiotropy discovery.
Genet Epidemiol. 2011 Jul;35(5):410-22. doi: 10.1002/gepi.20589. Epub 2011 May 18.
6
Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy.
Arthritis Rheum. 2011 Mar;63(3):713-21. doi: 10.1002/art.30156.
7
Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.
Pharmacogenomics J. 2012 Jun;12(3):233-7. doi: 10.1038/tpj.2010.92. Epub 2011 Jan 18.
8
Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study.
Clin Pharmacol Ther. 2011 Feb;89(2):210-6. doi: 10.1038/clpt.2010.255. Epub 2010 Dec 22.
9
Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction.
Pharmacogenomics. 2010 Aug;11(8):1065-76. doi: 10.2217/pgs.10.81.
10
Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs.
Pharmacogenomics J. 2011 Aug;11(4):274-86. doi: 10.1038/tpj.2010.28. Epub 2010 Apr 13.
Zotero 插件